[go: up one dir, main page]

DE69731660D1 - Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung - Google Patents

Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung

Info

Publication number
DE69731660D1
DE69731660D1 DE69731660T DE69731660T DE69731660D1 DE 69731660 D1 DE69731660 D1 DE 69731660D1 DE 69731660 T DE69731660 T DE 69731660T DE 69731660 T DE69731660 T DE 69731660T DE 69731660 D1 DE69731660 D1 DE 69731660D1
Authority
DE
Germany
Prior art keywords
linker
nucleic acid
vectors
expression
flanking region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731660T
Other languages
English (en)
Other versions
DE69731660T2 (de
Inventor
Michael Coleman
Robert Schwartz
J Demayo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Urigen Pharmaceuticals Inc
Original Assignee
Baylor College of Medicine
Urigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Urigen Pharmaceuticals Inc filed Critical Baylor College of Medicine
Application granted granted Critical
Publication of DE69731660D1 publication Critical patent/DE69731660D1/de
Publication of DE69731660T2 publication Critical patent/DE69731660T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69731660T 1996-12-02 1997-12-01 Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung Expired - Lifetime DE69731660T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3153996P 1996-12-02 1996-12-02
US31539P 1996-12-02
US97457297A 1997-11-19 1997-11-19
US974572 1997-11-19
PCT/US1997/021852 WO1998024922A1 (en) 1996-12-02 1997-12-01 Insulin-like growth factor i (igf-i) expression system and methods of use

Publications (2)

Publication Number Publication Date
DE69731660D1 true DE69731660D1 (de) 2004-12-23
DE69731660T2 DE69731660T2 (de) 2005-12-22

Family

ID=26707375

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731660T Expired - Lifetime DE69731660T2 (de) 1996-12-02 1997-12-01 Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung

Country Status (7)

Country Link
US (1) US20030018984A1 (de)
EP (1) EP0943003B1 (de)
JP (1) JP4131569B2 (de)
AT (1) ATE282707T1 (de)
CA (1) CA2274314C (de)
DE (1) DE69731660T2 (de)
WO (1) WO1998024922A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423693B1 (en) 1997-07-24 2002-07-23 Baylor College Of Medicine Growth hormone releasing hormone expression system and methods of use, including use in animals
US6723707B1 (en) * 1997-08-25 2004-04-20 The Trustees Of The University Of Pennsylvania Use of insulin-like growth factor-I in muscle
FR2783839B1 (fr) * 1998-09-25 2002-12-06 Aventis Pharma Sa Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
JP2002525109A (ja) * 1998-09-25 2002-08-13 アバンテイス・フアルマ・エス・アー 組織発現を調節するための特異的ハイブリッドプロモーターの使用
US6924365B1 (en) * 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6576618B1 (en) * 1999-06-22 2003-06-10 Research Development Foundation Methods to enhance wound healing and enhanced wound coverage material
ES2156769B1 (es) * 1999-11-26 2002-03-01 Univ Barcelona Autonoma Gen quimerico que permite expresar el gen o el cdna del factor de crecimiento similar a la insulina de tipo i (igf-i) en pancreas y su utilizacion para la terapia genica de la diabetes mellitus.
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
US7326417B2 (en) 2001-09-11 2008-02-05 Merial Ltd. IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
FR2829498B1 (fr) * 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
EP1603945A2 (de) * 2003-03-12 2005-12-14 Advisys, Inc. Plasmid-vermittelte ergänzung von insulinähnlichem wachstumsfaktor (igf-i) für therapeutische anwendungen
KR102000141B1 (ko) 2011-10-27 2019-07-15 웰스테이트 옵탈믹스 코퍼레이션 간상세포 유래 원추세포 생존능 인자를 인코딩하는 벡터
CN102978202A (zh) * 2012-10-10 2013-03-20 中国农业科学院北京畜牧兽医研究所 一种肌肉特异表达猪igf1基因的过表达载体
WO2018071465A1 (en) 2016-10-11 2018-04-19 Wellstat Ophthalmics Corporation Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
KR20210025122A (ko) * 2018-07-17 2021-03-08 주식회사 헬릭스미스 Igf-1-암호화 dna 작제물들 및 hgf-암호화 dna 작제물들을 사용한 신경병증 치료
SG11202100139VA (en) * 2018-07-17 2021-02-25 Neuromyon Inc Treatment of neuropathy with dna constructs expressing igf-1 isoforms
WO2020028194A1 (en) * 2018-07-30 2020-02-06 Readcoor, Inc. Methods and systems for sample processing or analysis
WO2020076976A1 (en) 2018-10-10 2020-04-16 Readcoor, Inc. Three-dimensional spatial molecular indexing
MX2021007241A (es) * 2018-12-19 2021-09-23 Versameb Ag Acido ribonucleico (arn) que codifica para una proteina.
US20220049303A1 (en) 2020-08-17 2022-02-17 Readcoor, Llc Methods and systems for spatial mapping of genetic variants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US6423693B1 (en) * 1997-07-24 2002-07-23 Baylor College Of Medicine Growth hormone releasing hormone expression system and methods of use, including use in animals

Also Published As

Publication number Publication date
CA2274314A1 (en) 1998-06-11
EP0943003B1 (de) 2004-11-17
JP4131569B2 (ja) 2008-08-13
US20030018984A1 (en) 2003-01-23
ATE282707T1 (de) 2004-12-15
DE69731660T2 (de) 2005-12-22
WO1998024922A1 (en) 1998-06-11
CA2274314C (en) 2007-03-13
EP0943003A1 (de) 1999-09-22
JP2001505435A (ja) 2001-04-24

Similar Documents

Publication Publication Date Title
DE69731660D1 (de) Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung
US6919208B2 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
HUT72987A (en) Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
NZ291689A (en) Peptide of 145 to 167 amino acids capable of modulating body weight in mammals
PL331005A1 (en) Regulating dna of hamster's ef-1alpha transcription
AU7833494A (en) Enhanced expression in plants using non-translated leader sequences
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
WO1998046781A3 (en) Novel transgene expression system for increased persistence
WO2001038357A3 (en) Jaffa, a novel fibroblast growth factor family member and uses therefor
EP1333088A4 (de) Paramyxovirus-vektor zur einführung von fremdgenen in skelettmuskel
ATE352561T1 (de) Pgc-1, ein neuartiger ppar-gamma-koaktivator aus braunem fettgewebe
MXPA04003944A (es) Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.
AU8435698A (en) Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
NZ332897A (en) Methods and compositions for modulating production of a T helper type 2 (Th2)-associated cytokine by regulating transcription factor activity in association with a Nuclear Factor of Activated T cells (NF-AT) protein
WO2004033653A3 (en) Gene regulation with aptamer and modulator complexes for gene therapy
ATE360688T1 (de) Dna-fragment, dieses enthaltender rekombinanter vektor und verfahren zur expression von fremdgenen unter dessen verwendung
EP0652948A4 (de) Entwicklung eines vektors zur erreichung von genexpression in der epidermis transgener tiere.
HUT65492A (en) Biosynthetic process for the preparation of dedydro-amino acid-remainds and tioether-bridge contaning chemical compounds
DE60028217D1 (de) Zyklische depsipeptid-synthasen, deren gene und system zur massenproduktion von zyklischen depsipeptiden
Oida et al. Cloning and sequence of bone morphogenetic protein 4 (BMP-4) from a human placental cDNA library
JPS5756495A (en) Novel dna-introduction vector and recombinant dna
WO2001082973A3 (en) Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
AU2001253258A1 (en) Human trp-like calcium channel protein-2 (tlcc-2)
ATA282386A (de) Verfahren zur expression von genen in hefe und dna-fragmente und diese dna-fragmente enthaltende plasmide zur verwendung bei diesem verfahren

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: VALENTIS INC., BURLINGAME, CALIF., US

Owner name: THE BAYLOR COLLEGE OF MEDICINE, HOUSTON, TEX., US

8364 No opposition during term of opposition